Reference pricing models are emerging as increasingly popular approaches for lowering drug costs.
Have two minutes? Listen to this quick podcast for critical takeaways from three of our top articles.
Healthcare experts weigh in on the president’s plan to lower drug prices. Here’s what they said.
The International Rare Diseases Research Consortium hopes to develop 200 new drugs for rare diseases by 2020, and it seems as if things are better than on track.
Some of the most amazing things are happening in the delivery of medical care these days. Surgical techniques, new devices, drugs, and diagnostics can treat and cure many medical conditions.
PBMs are in a unique position to leverage three critical tools to protect patients from unnecessary healthcare costs.
Two new studies reveal that cost-restraints can keep patients from accessing life-preserving cancer drugs.
A poll from the Biosimilars Council, a division of the Association for Accessible Medicines, has interesting findings about placing biosimilars and branded biologics on a level playing field to save money.
Autologous stem cell therapy may offer hope for patients with COPD. But some say caution is necessary.
CVS Health’s Troyen A. Brennan, MD, MPH, brings attention to a unique specialty pharmacy model and value-based contracting.